Resolution of Chronic Eosinophilic Pneumonia during Treatment with Benralizumab in Patient with Peripheric Blood Eosinophilia

Alessandra Giuliano¹, Francesca Mandreucci^1, , Alida Benfante², Maria Noemi Cicero², Gabriele Seminara², Nicola Scichilone², Antonio Carroccio¹, Erica Maria Bruno³, Daniele Castellucci³, Marta Chiavetta³, Stella Compagnoni³, Noemi Monachino³, Giulia Teresi³, Giuseppe Martorana³ and Simonetta Maisano³

¹Internal Medicine Unit, V. Cervello Hospital, Palermo, Italy;

²Pulmonology Unit, AOUP Paolo Giaccone Hospital, Palermo, Italy

³The Internal Medicine Unit Study Group (IMUSG)

Cite this paper

Alessandra Giuliano, Francesca Mandreucci, Alida Benfante, Maria Noemi Cicero, Gabriele Seminara, Nicola Scichilone, Antonio Carroccio, Erica Maria Bruno, Daniele Castellucci, Marta Chiavetta, Stella Compagnoni, Noemi Monachino, Giulia Teresi, Giuseppe Martorana and Simonetta Maisano. Resolution of Chronic Eosinophilic Pneumonia during Treatment with Benralizumab in Patient with Peripheric Blood Eosinophilia. American Journal of Medical Case Reports. 2021; 9(9):482-484. doi: 10.12691/AJMCR-9-9-10

Abstract

Chronic eosinophilic pneumonia is a rare idiopathic form of pneumonia. A differential diagnosis is crucial to distinguish idiopathic from secondary forms and it requires clinical, laboratory and imaging investigations. In this case report we present a case of Chronic eosinophilic pneumonia and discuss differential diagnosis in a patient with a history of uncontrolled chronic asthma and moderate peripheral eosinophilia. Benralizumab, an anti-Interleukin-5 receptor drug, was administered to our patient, who remained asymptomatic throughout a ten-month follow-up. Further studies are essential to confirm the favorable effect of this novel therapy for Chronic eosinophilic pneumonia.

Keywords

eosinophilia, benralizumab, chronic eosinophilic pneumonia, asthma, fever

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Campos LEM, and Pereira LFFF. Pulmonary eosinophilia. J Bras Pneumol 35. 6 (2009): 561-73.
[2]	Patterson R, Greenberger PA, Radin RC, et al. Allergic bronchopulmonary aspergillosis. Staging as an aid to management. Ann Intern Med. 1982, 96(3): 286-291.
[3]	Marchand E, Etienne-Mastroianni B, Chanez P, Lauque D, Leclerc P, Cordier JF. Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? Eur Respir J 2003, 22: 8-13.
[4]	Matsuse H, Shimoda T, Fukushima C, Matsuo N, Sakai H, Takao A, et al. Diagnostic problems in chronic eosinophilic pneumonia. J Int Med Res 1997, 25: 196-201.
[5]	Daimon T, Johkoh T, Sumikawa H, Honda O, Fujimoto K, Koga T, et al. Acute eosinophilic pneumonia: thin-section CT findings in 29 patients. Eur J Radiol 2008, 65: 462-7.
[6]	Cottin V. Eosinophilic Lung disease. Clin Chest Med 2016, 37: 535-56.
[7]	Nakahara Y, Hayashi S, Fukuno Y, Kawashima M, Yatsunami J. Increased interleukin-5 levels in bronchoalveolar lavage fluid is a major factor for eosinophil accumulation in acute eosinophilic pneumonia. Respiration 2001, 68: 389-95.
[8]	Kolbeck F, Kozhich A, Koike M, Peng L, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J. Allergy Clin. Immunol., 125 (6) (2010), pp. 1344-1353; 2.
[9]	Isomoto K, et al. “Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia.” Internal Medicine 59.9 (2020): 1195-1198.
[10]	Izumo T, et al. “Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia.” Respiratory Medicine Case Reports (2020): 101062.